Uncategorized

Otsuka America Pharmaceutical, Inc. and Lundbeck announce the U.S. Food and Drug Administration has approved the New Drug Application for ABILIFY ASIMTUFII® extended-release injectable suspension for intramuscular use, a once-every-two-months injection for the treatment of schizophrenia in adults or for maintenance monotherapy treatment of bipolar I disorder in adults.

Aditum Bio, the biotech investment firm cofounded in 2019 by former Novartis CEO Joe Jimenez and former President of the Novartis Institutes for BioMedical Research Dr. Mark Fishman, announced the formation of Vitalli Bio, a portfolio company created for the development of novel therapies for immunological disorders.

CEL-SCI Corporation, a Phase 3 cancer immunotherapy company, announced the pricing of its underwritten confidentially marketed public offering of 794,117 shares of common stock at an offering price of $1.70 per share.

Daewoong Pharmaceutical announced that it had signed a Global License Agreement for its autoimmune disease drug candidate DWP213388 with Vitalli Bio, a US biotechnology company, on April 28.

Hillstream BioPharma, Inc. announced the pricing of an underwritten public offering of 5,300,000 shares of its common stock.

Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, provided an activity report for the third quarter ended March 31, 2023.

Nicox SA announced that the New Drug Application for approval to commercialize ZERVIATE®, 0.24%, submitted in China by its exclusive Chinese partner, Ocumension Therapeutics, has been included in the priority review and approval process of National Medical Products Administration of the People’s Republic of China.

The vulnerability could result in an attacker gaining control of an instrument remotely and altering genomic data results, the agency said.

Teladoc raised its 2023 outlook following the first quarter results, which analysts said represented a strong start to the year.

The laboratory services provider said patients are returning to the healthcare system for routine care, but COVID testing has plummeted as the pandemic winds down.